Leukadherin 1 |
カタログ番号GC17263 |
白血球表面インテグリン CD11b/CD18 の特異的アゴニストであるロイカドヘリン 1 は、フィブリノーゲンに対する CD11b/CD18 依存性細胞接着を 4 μM の EC50 で増加させます。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 344897-95-6
Sample solution is provided at 25 µL, 10mM.
Leukadherin 1 is an activator of CD11b/CD18 [1].
CD11b/CD18 is a cell surface adhesion receptor that mediates immune functions and leukocyte migration and is expressed primarily in the cells of the innate immune system.
Leukadherin 1 is a CD11b/CD18 activator. Leukadherin 1 increased CD11b/CD18-dependent cell adhesion to fibrinogen with EC50 value of 4 μM [1]. Leukadherin 1 increased CD11b/CD18-dependent cell adhesion to its ligand ICAM-1. In K562 cells, leukadherin 1 increased the binding of CD11b/CD18 to ICAM-1 through the formation of long membrane tethers [2].
In the acute peritonitis mice model, leukadherin 1 significantly reduced neutrophil accumulation by 40% [1]. In a MHC mismatched orthotopic kidney transplantation mouse model, leukadherin 1 reduced interstitial leukocyte infiltration, glomerular damage, neointimal hyperplasia and prolonged survival from 48.5% (CsA only) to 100% (CsA and LA1) [3]. In newborn rats exposed to hyperoxia (85% O2), leukadherin 1 reduced both macrophage and neutrophil infiltration in the lungs [4].
References:
[1]. Maiguel D, Faridi MH, Wei C, et al. Small molecule-mediated activation of the integrin CD11b/CD18 reduces inflammatory disease. Sci Signal, 2011, 4(189): ra57.
[2]. Celik E1, Faridi MH, Kumar V, et al. Agonist leukadherin-1 increases CD11b/CD18-dependent adhesion via membrane tethers. Biophys J, 2013, 105(11): 2517-2527.
[3]. Khan SQ, Guo L, Cimbaluk DJ, et al. A small molecule b2 integrin agonist improves chronic kidney allograft survival by reducing leukocyte recruitment and accompanying vasculopathy. Front Med (Lausanne), 2014, 1: 45.
[4]. Jagarapu J, Kelchtermans J, Rong M, et al. Leukadherin-1 Attenuates Hyperoxia-induced Lung Injury in Neonatal Rats. Am J Respir Cell Mol Biol, 2015.
Cell experiment: | Supernatant cytokines are quantified after stimulation and culture for 18 h (monocytes) or 24 h (NK cells). Except for bead-based stimulation, all experiments are conducted using 100 µL cells in a 96-well plate format. NK cell stimuli are added as follows: (1) Syk inhibitor (1 μM), (2) Leukadherin-1 or dimethylsulphoxide (DMSO) (vector control) (7.5 μM). Shown to induce 82% of maximum response with negligible off-target effect, (3) anti-CD210 or isotype control (5 µg/mL), (4) 30-45 min after Leukadherin-1 NK cells are stimulated with combinations of IL-12 (10 ng/mL), IL-15 (30 ng/mL) or IL~18 (10 ng/mL): either IL-12 + IL-15 or IL-12 + IL-18. Monocytes are stimulated using pam3csk4 (TLR-2 agonist, 300 ng/mL) or R848 (TLR-7/8 agonist, 2 µg/mL). Supernatants are stored at −80ºC for < 1 month before quantification. To exclude non-specific Leukadherin-1-mediated cytotoxicity, the cell viability is assayed at 24 h using the CellTitre-Glo reagent. No significant loss of viability in comparison with the DMSO control is seen, concurring with published data in other cell types. |
References: [1]. Roberts AL, et al. The complement receptor 3 (CD11b/CD18) agonist Leukadherin-1 suppresses human innate inflammatory signalling. Clin Exp Immunol. 2016 Sep;185(3):361-71. |
Cas No. | 344897-95-6 | SDF | |
Chemical Name | (Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid | ||
Canonical SMILES | O=C(N(C1=S)CC2=CC=CC=C2)/C(S1)=C([H])/C(O3)=CC=C3C4=CC=C(C(O)=O)C=C4 | ||
Formula | C22H15NO4S2 | M.Wt | 421.49 |
溶解度 | DMF: 1 mg/ml,DMSO: 1 mg/ml,DMSO:PBS(pH 7.2) (1:2): 0.3 mg/ml | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 2.3725 mL | 11.8627 mL | 23.7254 mL |
5 mM | 0.4745 mL | 2.3725 mL | 4.7451 mL |
10 mM | 0.2373 mL | 1.1863 mL | 2.3725 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5
(Based on Reviews and 5 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *